Summary
Definition
History and exam
Key diagnostic factors
- chronic mood disorder lasting greater than 2 years
- depressive symptoms present for most of the day, most days
- no periods of euthymia in the past 2 years (1 year for children or adolescents)
- symptoms of major depression may be continuously present for 2 or more years
Other diagnostic factors
- no symptoms of mania/hypomania or schizophrenia
- absence of underlying medical conditions, drug use, or substance abuse that could cause the mood disorder
- fatigue or low energy
- low self-esteem
- poor concentration or difficulty making decisions
- feelings of hopelessness
- poor appetite or overeating
- sleep disturbance
Risk factors
- positive family history
- female sex
Diagnostic tests
1st tests to order
- clinical diagnosis
- CBC
- thyroid function tests
- metabolic panel
- Patient Health Questionnaire (PHQ-9)
- Beck Depression Inventory (BDI)
- Quick Inventory of Depressive Symptoms (QIDS)
Tests to consider
- vitamin D
- vitamin B12
- urine test
- testosterone level
- ECG
- neuroimaging
Treatment algorithm
all patients
Contributors
Authors
David J. Hellerstein, MD

Professor of Clinical Psychiatry
Columbia University Medical Center
Director, Depression Evaluation Service
New York State Psychiatric Institute
New York, NY
Disclosures
DJH has received research grants (through the Research Foundation for Mental Hygiene) from Compass Pathways, Relmada, Marinus, Intracellular Therapies, Beckley Scientific, Mind Medicine Inc., NIAMS (M Walker, PI, grant funding to Columbia University), and from Velocity Foundation (through Columbia University). DJH has received royalties from Johns Hopkins University Press, and Columbia University Press.
Acknowledgements
Dr David J. Hellerstein would like to gratefully acknowledge Dr David L. Dunner, a previous contributor to this topic.
Disclosures
DLD has received grant support from Cyberonics. DLD has received fees for consulting from: Eli Lilly, Pfizer, GlaxoSmithKline, Wyeth, Bristol-Myers Squibb, Forest, Cyberonics, Roche Diagnostics, Cypress, Corcept, Janssen, Novartis, Shire, Somerset, Otsuka, Healthcare Technology Sys, Jazz Pharma, Sanofi-Aventis, and MedAvante. DLD is on the Speaker's Bureau for: Eli Lilly, Pfizer, GlaxoSmithKline, Wyeth, Bristol-Myers Squibb, Organon, Jazz Pharma, Neuronetics, and Astra-Zeneca. DLD is an author of several references cited in this topic.
Peer reviewers
Balwinder Singh, MD, MS
Assistant Professor of Psychiatry
Mayo Clinic College of Medicine
Rochester, MN
Disclosures
BS reports research grant support from Mayo Clinic, the National Network of Depression Centers (NNDC), Breakthrough Discoveries for Thriving with Bipolar Disorder (BD2), and NIH. He is a KL2 Mentored Career Development Program scholar, supported by CTSA grant number KL2TR002379 from the National Center for Advancing Translational Science (NCATS). He has received honoraria (to institution) from Elsevier for editing a clinical overview on treatment-resistant depression.
Sagar V. Parikh, MD, FRCPC
Professor of Psychiatry
University of Michigan
Ann Arbor, MI
Disclosures
SVP has received research funding from Aifred, Janssen, Compass, and Sage, and has received consulting income from Aifred, Biogen, Boehringer Ingelheim, Otsuka, and Mensante.
Neil Nixon, BSc, MMedSci, MBBS, FRCPsych
Associate Professor in Psychiatry
Institute of Mental Health
University of Nottingham
Nottingham
UK
Disclosures
NN is a member of the current NICE GDG for depression in adults. NN has met with Jansen in a non-remunerative capacity. He has various research collaborations including a funded trial and is author on a number of papers.
Peer reviewer acknowledgements
BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.
Disclosures
Peer reviewer affiliations and disclosures pertain to the time of the review.
References
Key articles
American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed., text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022.
Lam RW, Kennedy SH, Adams C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 update on clinical guidelines for management of major depressive disorder in adults: réseau canadien pour les traitements de l'humeur et de l'anxiété (CANMAT) 2023 : mise à jour des lignes directrices cliniques pour la prise en charge du trouble dépressif majeur chez les adultes. Can J Psychiatry. 2024 Sep;69(9):641-87.Full text Abstract
National Institute for Health and Care Excellence. Depression in adults: treatment and management. Jun 2022 [internet publication].Full text
Bauer M, Severus E, Köhler S, et al; World Federation of Societies of Biological Psychiatry Task Force on Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 2: maintenance treatment of major depressive disorder - update 2015. World J Biol Psychiatry. 2015 Feb;16(2):76-95.Full text Abstract
Reference articles
A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
Differentials
- Adjustment disorder with depressed mood, persistent (chronic)
- Major depressive disorder
- Bipolar disorders (bipolar I, bipolar II, bipolar disorder not otherwise specified)
More DifferentialsGuidelines
- Recommendation on screening adults for depression using a screening tool
- Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 update on clinical guidelines for management of major depressive disorder in adults
More GuidelinesPatient information
Depression in adults: what is it?
Depression in adults: what are the treatment options?
More Patient informationLog in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer